AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02870231 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: liraglutide
Description: Once-daily subcutaneous (s.c., under the skin) administration.
Study NCT02870231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Once-daily subcutaneous (s.c., under the skin) administration
Study NCT02870231 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Once-daily subcutaneous (s.c., under the skin) administration
Study NCT00469612 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeuroVision's NVC treatment for Low Myopia
Description: NeuroVision's NVC vision correction technology is a method in the treatment of low myopia as the technology is directed at specific neuronal interactions at the level of the visual cortex (area responsible for vision in the brain).~The subject will be exposed to a set of visual stimulations (pattern with black and white lines) and visual threshold level will be obtained. The subject will look at these patterns on a computer. The treatment will be applied in successive 30-40 minute sessions, administered 2-3 times a week, for a total of 40 sessions. Every 5 sessions, subject's visual performance (visual acuity and CSF) will be tested in order to continuously monitor a subject's progress.
Study NCT04580290 — intervention group
Intervention type: DEVICE
Intervention: JewelACL
Description: The JewelACL is a polyester scaffold for anterior cruciate ligament (ACL) reconstruction
Study NCT02697383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib (MLN9708)
Study NCT02697383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study NCT03073135 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychodrama Group Therapy (PGT)
Description: The psychotherapeutic focus is on the here and now aspect of the patient's relationships. Conflicts are acted out during the sessions, yielding intense emotional re-experience in a safe environment, which will bring further cognitive understanding of past distressful life experiences and hopefully new adaptive ways of expressing and dealing with the problem.
Study NCT03073135 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Group Therapy (SGT)
Description: SGT is a form of treatment in which the therapist maintains a therapeutic relationship and a working alliance based on reality, support, clarification, assistance in troubleshooting, strong leadership, partial gratification of dependency needs, legitimating independence, development of pleasurable activities and adequate rest, guidance and advice to deal with current problems. This approach uses techniques to help patients feel safe, accepted, protected, encouraged and not anxious.
Study NCT02258880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SUN13837
Study NCT02258880 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT03206281 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Fetal wight estimation
Description: We will estimate the fetal weight by sonographic and clinical estimation
Study NCT02458937 — intervention group
Intervention type: OTHER
Intervention: Functional Mobility Assessment
Description: Functional Mobility Assessment (FMA) is a tool that was developed to measure functional mobility in children and adolescents with lower-extremity sarcoma. It is comprised of well-established outcome measures that examine various domains of function. The six categories tested by the FMA include pain, functional mobility, use of assistive devices, satisfaction with quality of gait, participation in the community, and endurance.
Study NCT02093442 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endometrial injury
Description: Endometrial biopsy using a pipelle de Cornier
Study NCT02458937 — intervention group
Intervention type: OTHER
Intervention: GAITRite® System
Description: Subjects will be required to walk at a self-selected comfortable pace and again at fast speed. Software will then calculate and report the temporo-spatial gait parameters for collection and evaluation by the primary investigator.
Study NCT03012074 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Type 2 Diabetes Self-Management
Description: Patients with Type 2 Diabetes
Study NCT03446885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine Dimesylate 40 MG
Description: Lisdexamfetamine Dimesylate 40 MG administered orally
Study NCT02458937 — intervention group
Intervention type: OTHER
Intervention: Range of Motion
Description: Measurements will include hip flexion, hip abduction and adduction, and hip internal and external rotation. Range of motion (ROM) will be attempted on bilateral lower extremities, however if post-operative ROM precautions are implemented, the involved extremity will not be measured. Goniometry is a reliable and valid measure for active and passive ROM when following standardized procedures.
Study NCT04494100 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TRONC
Description: injection of 3 to 7 mL of Ropivacaine 3.75 mg/ml per nerve (median and ulnar nerves) and infiltration of 2 ml of Ropivacaine 3.75 mg/ml laterally above the flexion fold of the wrist in order to block the branches of the lateral cutaneous nerve of the forearm, the terminal sensory branch of the musculocutaneous nerve.
Study NCT04494100 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TRONC
Description: injection of 3 to 7 mL of Ropivacaine 3.75 mg/ml per nerve (median and ulnar nerves) and infiltration of 2 ml of Ropivacaine 3.75 mg/ml laterally above the flexion fold of the wrist in order to block the branches of the lateral cutaneous nerve of the forearm, the terminal sensory branch of the musculocutaneous nerve.
Study NCT04494100 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: WALANT
Description: infiltration with 3 to 7 ml of 1% lidocaine (10 mg/ml) combined with 0.005 mg/ml epinephrine and 8.4% sodium bicarbonate in the subcutaneous area in front of the transverse ligament, between the thenar and hypothenar eminences, from the flexion fold of the wrist over a length of 5 cm.
Study NCT04494100 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tourniquet
Description: inflation pressure 75 to 100 mmHg above systolic blood pressure.
Study NCT04494100 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: troncular blocks with Ropivacaine 3.75 mg/ml
Study NCT03446885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsule administered orally
Study NCT03412409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: RIC preconditioning regimen consisted of cytarabine (2 g/m2/day, days -10 to -9), busulfan (3.2 mg/kg/day on days -8 to -6), cyclophosphamide (1.0 g/m2/day, days -5 to -4), fludarabine (30 mg/m-2/day, days -6 to -2), semustine (250 mg/m-2, day -3), and rabbit antithymocyte globulin (thymoglobulin, 2.5 mg/kg/d, days -5 to -2; Sanofi, France).
Study NCT02829021 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: FLIR ThermaCAM P-65
Description: Women recalled for assessment after positive screening mammography were offered dynamic infrared thermography before clinical mammography and further tests.
Study NCT02571010 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Standard Medical treatment
Description: Standard treatment with drugs and usual rehabilitation
Study NCT02571010 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard Medical treatment
Description: Standard treatment with drugs and usual rehabilitation
Study NCT02571010 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Medical treatment
Description: Standard treatment with drugs and usual rehabilitation
Study NCT02571010 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibrotactile stimulation
Description: Rehabilitation by vibrotactile stimulation at medical center
Study NCT02571010 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Stimulation with Vibradol device switched off
Description: Sham Rehabilitation at medical center but with Vibradol device switched off
Study NCT05461079 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: obtention of up to three semen samples
Description: sorting of spermatozoa with flow cytometry. In the presence of insufficient numbers of spermatozoa after sorting (\<15 mill), up to three semen samples will be collected.
Study NCT02480933 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral mastectomy
Description: Bilateral mastectomy and imaging study of cadaveric breasts
Study NCT02480933 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Biopsy of BI-RADS 3 and superior lesions
Study NCT04688294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacubitril-Valsartan
Description: 30 patients initially received Sacubitril/Valsartan at 24/26 mg twice daily orally then dose was doubled as tolerated every 2-4 weeks to reach the target maintenance dose 97 mg/103 mg twice daily
Study NCT04688294 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan
Description: 30 patients received valsartan, starting at a dose of 40 mg/day orally. The dose was then doubled every 1-2 weeks on the basis of their blood pressure to reach a dose of 160 mg once daily according to guideline-directed medical therapy.
Study NCT00374803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolic Acid (Myfortic)
Description: * Group 1: Mycophenolic Acid (Myfortic) 1080 mg twice daily (2160 mg/day) for two weeks, followed by 720 mg twice daily (1440 mg/day) thereafter~* Group 2: Mycophenolic Acid (Myfortic) 720 mg twice daily (1440 mg/day).
Study NCT00374803 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolic Acid (Myfortic)
Description: * Group 1: Mycophenolic Acid (Myfortic) 1080 mg twice daily (2160 mg/day) for two weeks, followed by 720 mg twice daily (1440 mg/day) thereafter~* Group 2: Mycophenolic Acid (Myfortic) 720 mg twice daily (1440 mg/day).
Study NCT02529579 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: iAPA-DC/CTL adoptive cellular immunotherapy
Description: twice DC cell infusion and CTL cell infusion for 6 times
Study NCT02529579 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: standard Gemcitabine therapy
Study NCT02529579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: standard Gemcitabine therapy
Study NCT01448395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]NXL104
Description: 500mg/100mL intravenous solution
Study NCT02290314 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: minimally invasive MID-line Lumbar Fusion (MIDLF)
Study NCT02290314 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Posterior lumbar interbody fusion (PLIF)
Study NCT03685773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diazoxide
Description: MRI studies: Non-diabetic and T2D participants will receive diazoxide (up to 7 mg/kg) between baseline MRI scan and second MRI scan.~Clamp studies: Non-diabetic participants will not require an overnight admission. They will receive diazoxide (up to 7 mg/kg) and undergo the pancreatic clamp study. Type 2 diabetic participants will be admitted the evening before the study day to normalize blood sugar levels. They will then receive diazoxide (up to 7 mg/kg) the next morning and undergo the pancreatic clamp study.
Study NCT04494100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: troncular blocks with Ropivacaine 3.75 mg/ml
Study NCT04494100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine + Epinephrine
Description: WALANT technique with 1% lidocaine (10 mg/ml) combined with 0.005 mg/ml epinephrine
Study NCT00154089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EM-1421
Description: EM-1421 administered intravaginally every 3 weeks as 45 mg (1% w/w) EM-1421 or 90 mg (2% w/w) EM-1421
Study NCT04586387 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intermittent theta burst stimulation (iTBS) with sham and then active stimulation over bicep muscle
Description: repetitive non-invasive brain stimulation protocol which feels like many quick, light taps on your head
Study NCT04586387 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intermittent theta burst stimulation (iTBS) with sham and then active stimulation over finger muscle
Description: repetitive non-invasive brain stimulation protocol which feels like many quick, light taps on your head
Study NCT03685773 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for diazoxide)
Description: MRI studies: Non-diabetic and T2D participants will receive placebo (for diazoxide) between baseline MRI scan and second MRI scan.~Clamp studies: Non-diabetic participants will not require an overnight admission. They will receive a taste-matched placebo (for diazoxide) and undergo the pancreatic clamp study. Type 2 diabetic participants will be admitted the evening before the study day to normalize blood sugar levels. They will then receive a taste-matched placebo (for diazoxide) the next morning and undergo the pancreatic clamp study.
Study NCT03685773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (for diazoxide)
Description: MRI studies: Non-diabetic and T2D participants will receive placebo (for diazoxide) between baseline MRI scan and second MRI scan.~Clamp studies: Non-diabetic participants will not require an overnight admission. They will receive a taste-matched placebo (for diazoxide) and undergo the pancreatic clamp study. Type 2 diabetic participants will be admitted the evening before the study day to normalize blood sugar levels. They will then receive a taste-matched placebo (for diazoxide) the next morning and undergo the pancreatic clamp study.
Study NCT03685773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotinic acid
Description: Type 2 diabetic participants in this arm will receive a nicotinic acid infusion to lower free fatty acid levels. They will then receive diazoxide (up to 7 mg/kg) the next morning and undergo the MRI or pancreatic clamp study.
Study NCT02498873 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Linear Periodization
Description: Linear Intensity Periodization Running
Study NCT02498873 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non Linear Periodization
Description: Non Linear Periodization Running
Study NCT04635306 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Approved GEBT test meal
Description: FDA-approve GEBT test meal
Study NCT03248726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyethylene glycol and bisacodyl
Description: Intervention: Take 3 tablets (15mg) of stimulant laxatives Dulcolax® (bisacodyl) at 10pm the day before examination. Take two pack of osmotic laxative Klean-prep® powder (Polyethylene glycol) mixed with 2000ml water at 5am on the morning of examination.
Study NCT03248726 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Split-dose polyethylene glycol
Description: Take two pack of Klean-prep® powder mixed with 2000ml water at 6pm before the day of examination, and take another two pack of osmotic laxative Klean-prep® powder mixed with 2000ml water at 5am on the examination day.
Study NCT04184817 — intervention group
Intervention type: OTHER
Intervention: Collection of clinical data registered in Easily software
Description: Collection of clinical data registered in Easily software
Study NCT00887861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Investigational new drug, company code: BGG492
Study NCT00887861 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02505282 — intervention group
Intervention type: OTHER
Intervention: Vitamin K status
Description: Vitamin K status indicated by desphospho-uncarboxylated matrix Gla protein level
Study NCT01180933 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: fish oil
Description: 400 mg of DHA and 150 mg of eicosapentaenoic acid per day
Study NCT01180933 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: folate
Description: 400 µg per day
Study NCT01180933 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: fish oil + folate
Description: 500 mg DHA, 150 mg eicosapentaenoic acid, 400 µg MTHF per day
Study NCT01180933 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: only vitamins and minerals as recommended, but no fish oil or folate
Study NCT01884831 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: study of the efficacy of skin equivalent comprising living cells and skin biodegradable substrate for the treatment of skin lesions
Study NCT02631538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belimumab
Description: Belimumab will be provided as a 200 mg sterile, liquid product in a prefilled syringe. Each syringe contains 1.0 mL of 200 mg/mL belimumab. Each syringe will be a single use.
Study NCT02631538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab will be provided as a 100 mg concentrated solution for infusion. It is a clear, colorless liquid.
Study NCT02631538 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Rituximab will be provided as a 100 mg concentrated solution for infusion. It is a clear, colorless liquid.
Study NCT02631538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo belimumab
Description: The placebo control will be provided as a sterile liquid product in a prefilled syringe. Each syringe will be of a single use.
Study NCT02631538 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo belimumab
Description: The placebo control will be provided as a sterile liquid product in a prefilled syringe. Each syringe will be of a single use.
Study NCT02631538 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo belimumab
Description: The placebo control will be provided as a sterile liquid product in a prefilled syringe. Each syringe will be of a single use.
Study NCT02631538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo rituximab
Description: Placebo rituximab will be provided as solution for infusion. It is a clear, colorless liquid.
Study NCT02631538 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo rituximab
Description: Placebo rituximab will be provided as solution for infusion. It is a clear, colorless liquid.
Study NCT04396509 — intervention group
Intervention type: BEHAVIORAL
Intervention: Maternal Attachment Inventory Score
Description: three month after delivery using Maternal Attachment Inventory (MAI) and a detailed history was taken.
Study NCT01964001 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin B-6
Description: Vitamin B-6 50 mg/d
Study NCT01964001 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10
Description: Coenzyme Q10 300 mg
Study NCT01964001 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin B-6+Coenzyme Q10
Description: Vitamin B-6 (50 mg/d) and Coenzyme Q10 (300 mg/d)
Study NCT02576184 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biologic Mesh
Description: Biologic mesh placed in retromuscular position during ileostoma closure
Study NCT02576184 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Synthetic Mesh
Description: synthetic mesh placed in retromuscular position during ileostoma closure
Study NCT03032380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefiderocol
Description: 2000 mg intravenously every 8 hours for a period of 7 to14 days (dosage adjustment is necessary based on renal function)
Study NCT03032380 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meropenem
Description: 2000 mg intravenously every 8 hours for a period of 7 to 14 days (dosage adjustment is necessary based on renal function)
Study NCT03032380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linezolid
Description: 600 mg of linezolid administered intravenously over 30 minutes to 2 hours, every 12 hours.
Study NCT03032380 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linezolid
Description: 600 mg of linezolid administered intravenously over 30 minutes to 2 hours, every 12 hours.
Study NCT01258569 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entereg
Description: Alvimopan (Entereg), an oral peripherally- acting mu-opioid receptor antagonist, is the first and only drug approved by the FDA to accelerate the time to upper and lower GI recovery in after partial large or small bowel resection surgery with primary anastomosis.
Study NCT01258569 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entereg
Description: oral, 12 mg 30-300 min pre-op then BID up to 7 days (or 15 total doses)
Study NCT01964001 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: starch
Study NCT02373111 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Isoflavone
Study NCT02373111 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Astaxanthin
Study NCT02373111 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01406067 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment Program for Children with Aggressive Behavior
Description: 24 sessions with the child aiming at the reduction of peer related aggressive behavior via social skills training. Additionally up to 10 sessions with relatives of the child in most cases with the parents.